AOBiome begins Phase II trial of AOB-based therapeutic for acne vulgaris
The Phase II trial is being conducted under an investigational new drug (IND) application to the US Food and Drug Administration (FDA) and is the first to test
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).
Progenics Pharmaceuticals has exclusively licensed development and commercialization rights for its first commercial product, Relistor, to Valeant. Relistor is a peripherally acting mu-opioid receptor antagonist designed to block